T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents
- PMID: 36587928
- PMCID: PMC9726683
- DOI: 10.1016/j.jamda.2022.11.024
T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents
Abstract
Objectives: Nursing home (NH) residents have been significantly affected by the coronavirus disease 2019 (COVID-19) pandemic. Studies addressing the immune responses induced by COVID-19 vaccines in NH residents have documented a good postvaccination antibody response and the beneficial effect of a third booster vaccine dose. Less is known about vaccine-induced activation of cell-mediated immune response in frail older individuals in the long term. The aim of the present study is to monitor messenger RNA SARS-CoV-2 vaccine-induced T-cell responses in a sample of Italian NH residents who received primary vaccine series and a third booster dose and to assess the interaction between T-cell responses and humoral immunity.
Design: Longitudinal cohort study.
Setting and participants: Thirty-four residents vaccinated with BNT162b2 messenger RNA SARS-CoV-2 vaccine between February and April 2021 and who received a third BNT162b2 booster dose between October and November 2021 were assessed for vaccine-induced immunity 6 (prebooster) and 12 (postbooster) months after the first BNT162b2 vaccine dose.
Methods: Pre- and postbooster cell-mediated immunity was assessed by intracellular cytokine staining of peripheral blood mononuclear cells stimulated in vitro with peptides covering the immunodominant sequence of SARS-CoV-2 spike protein. The simultaneous production of interferon-γ, tumor necrosis factor-α, and interleukin-2 was measured. Humoral immunity was assessed in parallel by measuring serum concentration of antitrimeric spike IgG antibodies.
Results: Before the booster vaccination, 31 out of 34 NH residents had a positive cell-mediated immunity response to spike. Postbooster, 28 out of 34 had a positive response. Residents without a previous history of SARS-CoV-2 infection, who had a lower response prior the booster administration, showed a greater increase of T-cell responses after the vaccine booster dose. Humoral and cell-mediated immunity were, in part, correlated but only before booster vaccine administration.
Conclusions and implications: The administration of the booster vaccine dose restored spike-specific T-cell responses in SARS-CoV-2 naïve residents who responded poorly to the first immunization, while a previous SARS-CoV-2 infection had an impact on the magnitude of vaccine-induced cell-mediated immunity at earlier time points. Our findings imply the need for a continuous monitoring of the immune status of frail NH residents to adapt future SARS-CoV-2 vaccination strategies.
Keywords: COVID-19 vaccines; SARS-CoV-2; cell-mediated immunity; nursing homes; vaccine booster.
Copyright © 2022. Published by Elsevier Inc.
Figures
Similar articles
-
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.Front Immunol. 2022 May 31;13:863554. doi: 10.3389/fimmu.2022.863554. eCollection 2022. Front Immunol. 2022. PMID: 35711445 Free PMC article.
-
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.Lancet Healthy Longev. 2021 Sep;2(9):e544-e553. doi: 10.1016/S2666-7568(21)00168-9. Epub 2021 Aug 19. Lancet Healthy Longev. 2021. PMID: 34430954 Free PMC article.
-
Humoral immunity induced by mRNA COVID-19 vaccines in Nursing Home Residents previously infected with SARS-CoV-2.Aging Clin Exp Res. 2022 Oct;34(10):2577-2584. doi: 10.1007/s40520-022-02239-0. Epub 2022 Sep 21. Aging Clin Exp Res. 2022. PMID: 36127623 Free PMC article.
-
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23. Lancet Healthy Longev. 2022. PMID: 35224524 Free PMC article.
-
Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.Influenza Other Respir Viruses. 2022 Nov;16(6):1066-1071. doi: 10.1111/irv.13030. Epub 2022 Aug 12. Influenza Other Respir Viruses. 2022. PMID: 35962568 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous